Administered slowly, low-dose infusions of tissue plasminogen activator (tPA) are associated with low mortality and high treatment success rates in patients with obstructive prosthetic valve ...
Andrew Blattman, CEO of IPH, tells Managing IP what’s next for the group in Canada and how it navigates issues such as conflicts and cost efficiency Australia-based listed company IPH has quickly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results